Showing 4041-4050 of 6035 results for "".
- Bausch + Lomb: No Immediate Plans to Go Privatehttps://modernod.com/news/bausch-lomb-no-immediate-plans-to-go-private/2482653/After exploring options to separate from Bausch Health, Bausch + Lomb announced Thursday it decided not to engage in a sale. “Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies
- Pykus Therapeutics to Present Initial Clinical Data on Novel Retinal Sealanthttps://modernod.com/news/pykus-therapeutics-to-present-initial-clinical-data-on-novel-retinal-sealant/2482651/Pykus Therapeutics announced that it will present initial clinical data on its investigational retinal sealant, PYK-2101, to replace gas and oil during retinal detachment repair. The data will be presented at the Vail Vitrectomy 2025 Meeting on February 10, 2025. The presentat
- AI Optics Receives FDA Clearance for Handheld Retinal Imaging Systemhttps://modernod.com/news/ai-optics-receives-fda-clearance-for-handheld-retinal-imaging-system/2482650/AI Optics has received FDA 510(k) clearance for its Sentinel Camera, a handheld retinal imaging system designed to capture high-quality images of the eye. Al Optics said the device helps to address critical gaps in retinal disease screening through a
- EyePoint Announces Positive 6-Month Results for the Phase 2 VERONA Clinical Trial of Duravyu for DMEhttps://modernod.com/news/eyepoint-announces-positive-6-month-results-for-the-phase-2-verona-clinical-trial-of-duravyu-for-dme/2482649/EyePoint Pharmaceuticals announced positive 6-month results for the ongoing phase 2 VERONA clinical trial evaluating Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME). Duravyu is an investigational sustained delivery therapy delivering vorolanib, a selective tyros
- Rayner Completes Recruitment for RayOne Galaxy IDE Studyhttps://modernod.com/news/rayner-completes-recruitment-for-rayone-galaxy-ide-study/2482642/Rayner announced the closure of recruitment in the Investigational Device Exemption (IDE) study for the RayOne Galaxy IOL in the United States. Developed in collaboration with Brazilian ophthalmologist João Lyra, MD, PhD, RayOne Galaxy is the worl
- BVI Medical Launches Educational Platform for Ophthalmology Professionalshttps://modernod.com/news/bvi-medical-launches-educational-platform-for-ophthalmology-professionals/2482639/BVI Medical announced the launch of EyeXchange Solutions, a platform designed to enhance vision care through comprehensive educational resources and clinical support. This initiative aims to empower surgical decision-making, enhance provider experiences, alleviate economic
- SeaBeLife Reports Promising In Vivo Results for Ophthalmic Gel Candidate for GAhttps://modernod.com/news/seabelife-reports-promising-in-vivo-results-for-it-ophthalmic-gel-candidate-for-ga/2482635/SeaBeLife announced in vivo results for its SBL03 drug candidate, an ophthalmic gel designed to combat necrotic retinal cell death in geographic atrophy (GA). The primary objective of the preclinical study was to assess
- Norlase Receives FDA 510(k) Clearance and CE Mark for LYNX Pattern Scanning Laser Indirect Ophthalmoscopehttps://modernod.com/news/norlase-receives-fda-510k-clearance-and-ce-mark-for-lynx-pattern-scanning-laser-indirect-ophthalmoscope/2482634/Norlase announced the FDA 510(k) clearance and CE Mark for Norlase LYNX, which the company describes as the world’s first and only pattern scanning laser indirect ophthalmoscope. Commercially available now, the LYNX is battery-powered and provides surgeons the abili
- RayOne EMV Toric IOL Approved by Health Canadahttps://modernod.com/news/rayone-emv-toric-iol-approved-by-health-canada/2482626/Rayner announced the approval of RayOne EMV Toric IOL by Health Canada. Developed in collaboration with Professor Graham Barrett, RayOne EMV and RayOne EMV Toric are the only patented aspheric IOLs that induce controlled positive spherical aberration to extend depth of focus, according
- Inflammasome Therapeutics Announces Positive Topline Data from K8 Implant Trial for GAhttps://modernod.com/news/inflammasome-therapeutics-announces-positive-topline-data-from-k8-implant-trial-for-geographic-atrophy/2482621/Inflammasome Therapeutics reported 3-month results from a clinical trial of its K8 implant in patients with geographic atrophy (GA). The study, conducted at the University of Kentucky (NCT06164587), demonstrated significant efficacy and safety following a single inject